Sava Infond d.o.o. Grows Stock Position in IQVIA Holdings Inc. $IQV

Sava Infond d.o.o. boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 33.3% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 14,290 shares of the medical research company’s stock after buying an additional 3,570 shares during the quarter. Sava Infond d.o.o.’s holdings in IQVIA were worth $2,252,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the business. Canada Pension Plan Investment Board grew its position in IQVIA by 7.3% in the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock valued at $810,069,000 after acquiring an additional 312,807 shares during the last quarter. JPMorgan Chase & Co. grew its position in IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock valued at $448,686,000 after acquiring an additional 798,534 shares during the last quarter. American Century Companies Inc. grew its position in IQVIA by 26.8% in the 1st quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company’s stock valued at $253,695,000 after acquiring an additional 304,258 shares during the last quarter. Dimensional Fund Advisors LP grew its position in IQVIA by 2.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company’s stock valued at $251,852,000 after acquiring an additional 40,699 shares during the last quarter. Finally, Pacer Advisors Inc. grew its position in IQVIA by 5,036.1% in the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock valued at $153,681,000 after acquiring an additional 854,732 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of IQV stock opened at $206.84 on Friday. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $237.34. The stock’s 50-day moving average is $187.90 and its 200 day moving average is $167.69. The company has a market cap of $35.16 billion, a P/E ratio of 29.93, a PEG ratio of 2.24 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter last year, the company earned $2.64 earnings per share. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Transactions at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of the firm’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider owned 2,910 shares of the company’s stock, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Eric Sherbet sold 5,800 shares of the firm’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have commented on IQV shares. Jefferies Financial Group raised IQVIA from a “hold” rating to a “buy” rating and upped their price objective for the company from $195.00 to $225.00 in a research report on Tuesday, September 9th. Mizuho increased their price target on IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Redburn Partners set a $214.00 price target on IQVIA in a research report on Wednesday, September 3rd. Finally, Cowen reissued a “buy” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Eighteen equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $230.32.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.